NA Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2033

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 DBMR TRIPOD DATA VALIDATION MODEL 35
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.6 MULTIVARIATE MODELLING 39
2.7 MARKET END USER COVERAGE GRID 40
2.8 PROCESS LIFELINE CURVE 41
2.9 DBMR MARKET POSITION GRID 42
2.10 VENDOR SHARE ANALYSIS 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 PESTEL ANALYSIS 51
4.2 POTERS FIVE FORCES 52
5 NORTH AMERICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 53
6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 59
6.1.2 RISE IN CHRONIC DISEASES 59
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 60
6.1.4 GROWTH IN BIOLOGICS 61
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 61

6.2 RESTRAINTS 62
6.2.1 RISE IN COST OF FORMULATED DRUG 62
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 62
6.3 OPPORTUNITIES 63
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 63
6.3.2 RISE IN HEALTHCARE EXPENDITURE 63
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 64
6.4 CHALLENGES 64
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 64
6.4.2 STRINGENT REGULATIONS 65
7 IMPACT OF COVID-19 ON NORTH AMERICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 66
7.1 IMPACT ON PRICE 66
7.2 IMPACT ON DEMAND 66
7.3 IMPACT ON SUPPLY CHAIN 67
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 67
7.5 CONCLUSION 68
8 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 69
8.1 OVERVIEW 70
8.2 TARGET SELECTION 73
8.3 TARGET VALIDATION 73
8.4 HIT-TO-LEAD IDENTIFICATION 74
8.5 LEAD OPTIMIZATION 75
8.6 CANDIDATE VALIDATION 76
9 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 77
9.1 OVERVIEW 78
9.2 FRAGMENT-BASED VARIATION 81
9.3 STRUCTURE BASED DRUG DESIGN 81
9.4 DIVERSITY ORIENTED SYNTHESIS 82
9.5 CHEMOGENOMICS 83
9.6 NATURAL PRODUCTS 84
9.7 OTHERS 85
10 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 86
10.1 OVERVIEW 87
10.2 SMALL MOLECULES 90
10.3 BIOLOGICS 91
11 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 92
11.1 OVERVIEW 93
11.2 ONCOLOGY 96
11.3 NEUROLOGY 96
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 97
11.5 CARDIOVASCULAR DISEASES 98
11.6 DIGESTIVE SYSTEM DISEASES 99
11.7 OTHERS 100
12 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 101
12.1 OVERVIEW 102
12.2 CONTRACT RESEARCH ORGANIZATION 106
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 106
12.4 ACADEMIC AND RESEARCH INSTITUTES 107
12.5 OTHERS 108
13 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY REGION 109
13.1 NORTH AMERICA 110
13.1.1 U.S. 116
13.1.2 CANADA 118
13.1.3 MEXICO 120
14 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 122
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 122
15 SWOT ANALYSIS 123

16 COMPANY PROFILE 124
16.1 EUROFINS SCIENTIFIC 124
16.1.1 COMPANY SNAPSHOT 124
16.1.2 REVENUE ANALYSIS 125
16.1.3 COMPANY SHARE ANALYSIS 125
16.1.4 SERVICE PORTFOLIO 125
16.1.5 RECENT DEVELOPMENT 126
16.2 LABCORP DRUG DEVELOPMENT 127
16.2.1 COMPANY SNAPSHOT 127
16.2.2 REVENUE ANALYSIS 128
16.2.3 COMPANY SHARE ANALYSIS 128
16.2.4 SERVICE PORTFOLIO 129
16.2.5 RECENT DEVELOPMENT 129
16.3 CHARLES RIVER 130
16.3.1 COMPANY SNAPSHOT 130
16.3.2 REVENUE ANALYSIS 130
16.3.3 COMPANY SHARE ANALYSIS 131
16.3.4 SERVICE PORTFOLIO 131
16.3.5 RECENT DEVELOPMENTS 131
16.4 WUXI APPTEC 132
16.4.1 COMPANY SNAPSHOT 132
16.4.2 REVENUE ANALYSIS 132
16.4.3 COMPANY SHARE ANALYSIS 133
16.4.4 SERVICE PORTFOLIO 133
16.4.5 RECENT DEVELOPMENTS 133
16.5 EVOTEC SE 134
16.5.1 COMPANY SNAPSHOT 134
16.5.2 REVENUE ANALYSIS 134
16.5.3 COMPANY SHARE ANALYSIS 135
16.5.4 SERVICE PORTFOLIO 135
16.5.5 RECENT DEVELOPMENTS 135
16.6 PIRAMAL PHARMA SOLUTIONS 136
16.6.1 COMPANY SNAPSHOT 136
16.6.2 SERVICE PORTFOLIO 136
16.6.3 RECENT DEVELOPMENTS 136
16.7 THERMO FISHER SCIENTIFIC INC. 137
16.7.1 COMPANY SNAPSHOT 137
16.7.2 REVENUE ANALYSIS 137
16.7.3 SERVICE PORTFOLIO 138
16.7.4 RECENT DEVELOPMENT 138
16.7.4.1 ACQUISITION 138
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 139
16.8.1 COMPANY SNAPSHOT 139
16.8.2 REVENUE ANALYSIS 139
16.8.3 SERVICE PORTFOLIO 140
16.8.4 RECENT DEVELOPMENT 140
16.9 AURELIA BIOSCIENCES 141
16.9.1 COMPANY SNAPSHOT 141
16.9.2 SERVICE PORTFOLIO 141
16.9.3 RECENT DEVELOPMENTS 141
16.10 BIOBLOCKS INC 142
16.10.1 COMPANY SNAPSHOT 142
16.10.2 SERVICE PORTFOLIO 142
16.10.3 RECENT DEVELOPMENT 142
16.11 CERTARA INC 143
16.11.1 COMPANY SNAPSHOT 143
16.11.2 REVENUE ANALYSIS 143
16.11.3 SERVICE PORTFOLIO 144
16.11.4 RECENT DEVELOPMENTS 144
16.12 DOMAINEX 145
16.12.1 COMPANY SNAPSHOT 145
16.12.2 SERVICE PORTFOLIO 145
16.12.3 RECENT DEVELOPMENT 145
16.13 DRUG DISCOVERY ALLIANCES 146
16.13.1 COMPANY SNAPSHOT 146
16.13.2 SERVICE PORTFOLIO 146
16.13.3 RECENT DEVELOPMENT 146
16.14 GENSCRIPT BIOTECH 147
16.14.1 COMPANY SNAPSHOT 147
16.14.2 REVENUE ANALYSIS 147
16.14.3 SERVICE PORTFOLIO 148
16.14.4 RECENT DEVELOPMENT 148
16.15 JUBILANT BIOSYS 149
16.15.1 COMPANY SNAPSHOT 149
16.15.2 SERVICE PORTFOLIO 149
16.15.3 RECENT DEVELOPMENTS 149
16.16 NANOSYN 151
16.16.1 COMPANY SNAPSHOT 151
16.16.2 PRODUCT PORTFOLIO 151
16.16.3 RECENT DEVELOPMENT 151
16.17 NEREID THERAPEUTICS 152
16.17.1 COMPANY SNAPSHOT 152
16.17.2 SERVICE PORTFOLIO 152
16.17.3 RECENT DEVELOPMENT 152
16.18 PFIZER INC. 153
16.18.1 COMPANY SNAPSHOT 153
16.18.2 REVENUE ANALYSIS 153
16.18.3 SERVICE PORTFOLIO 154
16.18.4 RECENT DEVELOPMENTS 154
16.19 SELVITA 155
16.19.1 COMPANY SNAPSHOT 155
16.19.2 REVENUE ANALYSIS 155
16.19.3 SERVICE PORTFOLIO 156
16.19.4 RECENT DEVELOPMENTS 156
16.19.4.1 ACQUISITION 156
16.20 SPECTRIS PLC 157
16.20.1 COMPANY SNAPSHOT 157
16.20.2 REVENUE ANALYSIS 157
16.20.3 SERVICE PORTFOLIO 158
16.20.4 RECENT DEVELOPMENT 158
16.21 SYGNATURE DISCOVERY 159
16.21.1 COMPANY SNAPSHOT 159
16.21.2 SERVICE PORTFOLIO 159
16.21.3 RECENT DEVELOPMENTS 159
16.22 TAROS CHEMICAL GMBH 160
16.22.1 COMPANY SNAPSHOT 160
16.22.2 SERVICE PORTFOLIO 160
16.22.3 RECENT DEVELOPMENT 160
17 QUESTIONNAIRE 161
18 RELATED REPORTS 164